Crescent Biopharma CBIO
NASDAQ CBIO
$16.23 -1.09 (-6.29%)
At close: Aug 20, 2026 · 4:00 PM EDT

Crescent Biopharma (CBIO) Operating Margin (2013 - 2026)

Crescent Biopharma (CBIO) posted quarterly Operating Margin of 2380.08% for Q1 2026, up 86.63% quarter-over-quarter from 17804.21% in Q2 2022.

Crescent Biopharma (CBIO) Operating Margin (2013 - 2026) Analysis & Trends

Crescent Biopharma (CBIO) has reported Operating Margin for 8 consecutive years, with 2380.08% the latest figure, recorded in Q1 2026.

  • In Q1 2026, Operating Margin changed N/A year-over-year to 2380.08%; the TTM figure through Jun 2026 stood at 16214.63% (changed N/A YoY), while the FY2025 annual figure was 1407.52%, changed N/A from the prior year.
  • Operating Margin rose to 2380.08% in Q1 2026 per CBIO's latest filing, from 17804.21% in the prior quarter.
  • Across five years, Operating Margin topped out at 2380.08% in Q1 2026 and bottomed at 17804.21% in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn 37.40%
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn 30.15%
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn 32.54%
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn -562.07%
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn 19.06%
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn 17.93%
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn -0.36%
8 Royalty Pharma 26.98 Bn 26.14 Bn - 19.75%
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn -35.57%
10 Crescent Biopharma 1.05 Bn 875.92 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 -2,380.08%
Jun 30, 2022 -17,804.21%
Dec 31, 2021 -98,870.20%
Sep 30, 2021 -20,028.82%
Jun 30, 2021 -10,144,001.41%
Mar 31, 2021 -1,352.98%
Dec 31, 2020 -9,554.94%
Sep 30, 2020 -1,372.73%
Mar 31, 2020 -90.09%
Sep 30, 2016 -42,631.11%
Dec 31, 2015 -25,123.75%
Sep 30, 2015 -20,272.43%
Jun 30, 2015 51.93%
Jun 30, 2014 53.66%
Dec 31, 2013 -4,995.73%
Sep 30, 2013 -7,039.81%
Jun 30, 2013 -6,349.56%
Mar 31, 2013 12.05%